国际流行病学传染病学杂志
國際流行病學傳染病學雜誌
국제류행병학전염병학잡지
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY AND INFECTIOUS DISEASE
2009年
1期
27-29
,共3页
肝炎,乙型,慢性%儿童%治疗
肝炎,乙型,慢性%兒童%治療
간염,을형,만성%인동%치료
Hepatitis B,chronic%Children%Treatment
目的 评价拉米夫定联合左旋咪唑涂布剂治疗HBeAg阳性儿童慢性乙型肝炎的近、远期疗效,以探讨治疗儿童慢性乙型肝炎的有效方法.方法 采用统一检测方法和评价标准,分析拉米夫定联合左旋咪唑涂布剂治疗HBeAg阳性的儿童慢性乙型肝炎(儿童组)的近期疗效、HBV YMDO发生率及停药后的远期疗效,并与同期治疗的HBeAg阳性成人慢性乙型肝炎(A组:拉米夫定+左旋咪唑涂布剂与B组:单用拉米夫定)的相关指标比较,进行X2检测.结果 儿童组与成人A组及成人B组治疗结束时,血清学、病毒学、生化学单项应答率分别为52.4%:34.0%:28.5%;90.5%:74.9%:62.8%;85.7%:82.9%:75.9%;完全应答率分别为52.4%、32.0%、25.5%;HBV YMDD变异率分别为14.3%、18.0%、32.1%;停药后1年持久应答率分别为90.9%、75.0%、51.4%.儿童组与成人A组各项疗效差异均无统计学意义,疗效基本相同,完全应答率虽优于成人A组,但差异无统计学意义.儿童组与成人B组相比,血清学、病毒学应答率、联合应答完全应答率及1年持久应答率均显著优于成人B组(P<0.05),而其他各项疗效差异均无统计学意义(P>0.05).结论 对ALT≥正常上限2倍的儿童慢性乙型肝炎,拉米夫定联合左旋咪唑涂布剂治疗的近远期疗效均明显优于单用拉米夫定者.
目的 評價拉米伕定聯閤左鏇咪唑塗佈劑治療HBeAg暘性兒童慢性乙型肝炎的近、遠期療效,以探討治療兒童慢性乙型肝炎的有效方法.方法 採用統一檢測方法和評價標準,分析拉米伕定聯閤左鏇咪唑塗佈劑治療HBeAg暘性的兒童慢性乙型肝炎(兒童組)的近期療效、HBV YMDO髮生率及停藥後的遠期療效,併與同期治療的HBeAg暘性成人慢性乙型肝炎(A組:拉米伕定+左鏇咪唑塗佈劑與B組:單用拉米伕定)的相關指標比較,進行X2檢測.結果 兒童組與成人A組及成人B組治療結束時,血清學、病毒學、生化學單項應答率分彆為52.4%:34.0%:28.5%;90.5%:74.9%:62.8%;85.7%:82.9%:75.9%;完全應答率分彆為52.4%、32.0%、25.5%;HBV YMDD變異率分彆為14.3%、18.0%、32.1%;停藥後1年持久應答率分彆為90.9%、75.0%、51.4%.兒童組與成人A組各項療效差異均無統計學意義,療效基本相同,完全應答率雖優于成人A組,但差異無統計學意義.兒童組與成人B組相比,血清學、病毒學應答率、聯閤應答完全應答率及1年持久應答率均顯著優于成人B組(P<0.05),而其他各項療效差異均無統計學意義(P>0.05).結論 對ALT≥正常上限2倍的兒童慢性乙型肝炎,拉米伕定聯閤左鏇咪唑塗佈劑治療的近遠期療效均明顯優于單用拉米伕定者.
목적 평개랍미부정연합좌선미서도포제치료HBeAg양성인동만성을형간염적근、원기료효,이탐토치료인동만성을형간염적유효방법.방법 채용통일검측방법화평개표준,분석랍미부정연합좌선미서도포제치료HBeAg양성적인동만성을형간염(인동조)적근기료효、HBV YMDO발생솔급정약후적원기료효,병여동기치료적HBeAg양성성인만성을형간염(A조:랍미부정+좌선미서도포제여B조:단용랍미부정)적상관지표비교,진행X2검측.결과 인동조여성인A조급성인B조치료결속시,혈청학、병독학、생화학단항응답솔분별위52.4%:34.0%:28.5%;90.5%:74.9%:62.8%;85.7%:82.9%:75.9%;완전응답솔분별위52.4%、32.0%、25.5%;HBV YMDD변이솔분별위14.3%、18.0%、32.1%;정약후1년지구응답솔분별위90.9%、75.0%、51.4%.인동조여성인A조각항료효차이균무통계학의의,료효기본상동,완전응답솔수우우성인A조,단차이무통계학의의.인동조여성인B조상비,혈청학、병독학응답솔、연합응답완전응답솔급1년지구응답솔균현저우우성인B조(P<0.05),이기타각항료효차이균무통계학의의(P>0.05).결론 대ALT≥정상상한2배적인동만성을형간염,랍미부정연합좌선미서도포제치료적근원기료효균명현우우단용랍미부정자.
Objective To analyze the therapeutic effect of chronic hepatitis B of HBeAg positive children by combination of lamivudine and liniment levamisole, to explore the suitable treatment of chronic hepatitis B of children. Method By adoptting the uniform detection and evaluation, to analyze the treatment for children with HBeAg positive chronic hepatitis B (group of children) by combination of lamivudine and liniment levamisole in the near future, the rate of occurrence of HBV YMDD and the curative effect of far future when stopping treatment, and to be compared with the corresponding index of the treatment in the adults of group A(lamivudine + liniment levrmisole) of HBeAg positive and the adults of group B(lamivudine only) at the same time through χ2 test. Results At the end of the treatment, the group of children and group A and group B, the single responding rate of serology and virology, biochemistry were 52.4%:34.0%:28.5%; 90.5%:74.9%:62.8%;85.7%:82.9%:75.9% respectively; the complete responding rate was 52.4%, 32.0%, 25.5%; the rate of occurrence of HBV YMDD was 14.3%, 18.0%, 32.1%; while stopping treatment for 1 year,the persistence responding rate were 90.9%, 75.0%, 51.4%. There were no statistical differences in all kinds of the creative effects in the group of children and group A of adults. The complete responding rate in the gronp of children was higher than that in group A of adults, but there was no statistical difference. By compering to the group B of adults, the single responding rate of serology and virology, the complete responding rate and the 1 year's persistence responding in the group of children were all much higher(P<0.05), there were no statistical differences in all of the other curative effects(P>0.05).Conclusions For the chronic hepatitis B of children (the ALT is more than or equal to the normal upper limit), the complete responding and the curative effects of lamivudine and liniment levamisole are better than by using larnivudine only.
